PMID: 9547441Apr 21, 1998Paper

Nebivolol in the treatment of cardiac failure: a double-blind controlled clinical trial

Journal of Cardiac Failure
O UhlirL Van Nueten

Abstract

Nebivolol is a highly cardioselective long-acting beta-blocker with vasodilating properties, which acts in part via the endothelial L-arginine/nitric oxide pathway. As an antihypertensive drug it is effective in once-daily dosage. Nebivolol has previously been shown to improve left ventricular function in patients with cardiac impairment. This paper reports a double-blind randomized trial comparing, in patients with heart failure, once-daily nebivolol 2.5 or 5.0 mg (initiated in all at 2.5 mg) with placebo on a constant background of digitalis plus diuretic. There was with nebivolol no overall deterioration of cardiac function or cardiac symptoms, and especially not of exercise capacity, in comparison with placebo. One patient on nebivolol 2.5 mg developed hypotension and pulmonary edema, and one patient on nebivolol 5 mg, bradycardia. All the remaining patients continued with unchanged diuretic and digitalis dosage. Nebivolol was accompanied by a trend toward clinical and functional improvement; rather better results were obtained with 2.5 than 5.0 mg. In view of increasing interest in beta-blockade in heart failure, nebivolol merits further study in this context. The capacity of nebivolol to enhance endothelial nitric oxide p...Continue Reading

References

Apr 1, 1995·Cardiovascular Drugs and Therapy·V PanfilovG Olsson
Sep 1, 1994·British Journal of Clinical Pharmacology·A J BowmanG A Ford
May 23, 1996·The New England Journal of Medicine·M A Pfeffer, L W Stevenson
May 4, 1996·Lancet·J G Cleland, K Swedberg
Feb 1, 1997·Journal of Human Hypertension·L Van NuetenJ I Robertson

❮ Previous
Next ❯

Citations

Dec 16, 1998·Clinical Cardiology·M R BristowE J Eichhorn
Aug 23, 2006·Cardiology in Review·Sachin S Sule, William Frishman
Mar 26, 1999·BMJ : British Medical Journal·J G ClelandN Freemantle
Aug 27, 2013·PloS One·Catherine E EricksonBradley T Andresen
Mar 29, 2012·Vascular Health and Risk Management·Jorge Eduardo ToblliFernando Pablo Dominici
Aug 18, 2006·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Renzo M R LombardoStefano De Castro
Dec 15, 2007·Vascular Health and Risk Management·Angie Veverka, Jennifer L Salinas
Apr 23, 2014·The Canadian Journal of Cardiology·Jonathan G Howlett
Jul 17, 2015·Drugs·Justin Fongemie, Erika Felix-Getzik
Jul 31, 2007·Expert Opinion on Pharmacotherapy·Rudolf A de BoerDirk J van Veldhuisen
Oct 11, 2011·Expert Opinion on Investigational Drugs·Nicoletta Riva, Gregory Y H Lip
Oct 10, 2009·Journal of the American College of Cardiology·Thomas Münzel, Tommaso Gori
Mar 24, 2010·Expert Opinion on Pharmacotherapy·Erik Lipsic, Dirk J van Veldhuisen
Mar 28, 2007·Heart Failure Clinics·John G F ClelandJonathan Windram
Jan 29, 2002·Journal of Cardiovascular Pharmacology·P M JanssenG Hasenfuss
Jan 29, 2002·Journal of Cardiovascular Pharmacology·E AmbrosioniC Borghi
May 7, 2011·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Allison S DeryJessica A Starr
Apr 12, 2008·Expert Review of Cardiovascular Therapy·David Wojciechowski, Vasilios Papademetriou
Oct 6, 2016·Experimental and Therapeutic Medicine·Xiaojian ZhangLi Han

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Bradyarrhythmias

Bradyarrhythmias are slow heart rates. Symptoms may include syncope, dizziness, fatigure, shortness of breath, and chest pains. Find the latest research on bradyarrhythmias here.